Schwab I - Search Results

1

Targeting B cells and autoantibodies in the therapy of autoimmune diseases.

Kao D, Lux A, Schwab I, Nimmerjahn F. Kao D, et al. Among authors: schwab i. Semin Immunopathol. 2014 May;36(3):289-99. doi: 10.1007/s00281-014-0427-7. Epub 2014 Apr 29. Semin Immunopathol. 2014. PMID: 24777745 Review.

2

The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Böhm S, Schwab I, Lux A, Nimmerjahn F. Böhm S, et al. Among authors: schwab i. Semin Immunopathol. 2012 May;34(3):443-53. doi: 10.1007/s00281-012-0308-x. Epub 2012 Mar 22. Semin Immunopathol. 2012. PMID: 22437760 Review.

3

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Schwab I, Nimmerjahn F. Schwab I, et al. Nat Rev Immunol. 2013 Mar;13(3):176-89. doi: 10.1038/nri3401. Epub 2013 Feb 15. Nat Rev Immunol. 2013. PMID: 23411799 Review.

4

Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice.

Schwab I, Lux A, Nimmerjahn F. Schwab I, et al. Cell Rep. 2015 Oct 20;13(3):610-620. doi: 10.1016/j.celrep.2015.09.013. Epub 2015 Oct 8. Cell Rep. 2015. PMID: 26456831 Free article.

5

Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.

Schwab I, Nimmerjahn F. Schwab I, et al. Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):97-9. doi: 10.1111/cei.12527. Clin Exp Immunol. 2014. PMID: 25546778 Free PMC article. No abstract available.

6

Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo.

Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F. Biburger M, et al. Among authors: schwab i. Immunity. 2011 Dec 23;35(6):932-44. doi: 10.1016/j.immuni.2011.11.009. Epub 2011 Dec 8. Immunity. 2011. PMID: 22169040 Free article.

7

IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.

Schwab I, Biburger M, Krönke G, Schett G, Nimmerjahn F. Schwab I, et al. Eur J Immunol. 2012 Apr;42(4):826-30. doi: 10.1002/eji.201142260. Eur J Immunol. 2012. PMID: 22278120 Free article.

8

FcγRIIB: a modulator of cell activation and humoral tolerance.

Lehmann B, Schwab I, Böhm S, Lux A, Biburger M, Nimmerjahn F. Lehmann B, et al. Among authors: schwab i. Expert Rev Clin Immunol. 2012 Mar;8(3):243-54. doi: 10.1586/eci.12.5. Expert Rev Clin Immunol. 2012. PMID: 22390489 Review.

9

B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.

Schwab I, Seeling M, Biburger M, Aschermann S, Nitschke L, Nimmerjahn F. Schwab I, et al. Eur J Immunol. 2012 Dec;42(12):3302-9. doi: 10.1002/eji.201242710. Epub 2012 Oct 16. Eur J Immunol. 2012. PMID: 22945870 Free article.

10

Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.

Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Schwab I, et al. Eur J Immunol. 2014 May;44(5):1444-53. doi: 10.1002/eji.201344230. Epub 2014 Mar 7. Eur J Immunol. 2014. PMID: 24505033 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208 results

Search Page

Filters